Futura Medical plc has terminated its agreement with Haleon for Eroxon® in the US market, receiving a $1.9 million early termination fee in exchange for the return of US commercial rights and marketing materials. The company has secured a new distribution partner, Market Performance Group (MPG), a leading omnichannel commerce agency, to manage Eroxon® distribution and promotion starting September 1, 2026. This strategic shift from a "launch and step back" to an "actively manage and optimise" model is expected to provide greater control and improved economic participation, with the termination fee and existing cash position supporting working capital into October 2026.
